Last updated: May 24, 2026
Palonosetron hydrochloride is supplied as a branded injectable product in the US market (Aloxi) and in generic equivalents abroad and in the US through ANDA pathways, depending on FDA approval status by label and strength. The drug’s supply chain splits into (1) API manufacturers for the palonosetron hydrochloride active ingredient and (2) finished-dose manufacturers for the injection (typically 0.25 mg/5 mL).
Because supplier visibility is governed by FDA submissions, DMFs, and commercial sourcing disclosures, supplier lists in the public domain are inconsistent across jurisdictions and time.
Who supplies palonosetron hydrochloride (API) in finished injection supply chains?
Answer: API supply is handled by DMF-holding manufacturers and contract API producers that feed finished-dose manufacturers for palonosetron hydrochloride injection. Public sources typically do not provide a complete, current “all suppliers” list without pairing FDA DMF data to current ANDA/market authorization holders.
Common supplier archetypes seen in palonosetron’s market structure
- DMF holders / API manufacturers that file drug master files supporting finished-dose manufacture.
- Contract manufacturers for sterile injectables handling aseptic filling, labeling, and packaging.
- Finished-dose marketing authorization holders (originator and ANDA filers) who may own no manufacturing sites and outsource to CMO/sterile fill-finish partners.
Which companies manufacture the FDA-approved palonosetron hydrochloride injection (Aloxi and generics)?
Answer: The US market is anchored by Aloxi (originator) and may include ANDA generics depending on strength and label. Finished-dose “suppliers” are typically the product holder plus the contract sterile manufacturer, which is not always listed in public-facing FDA summaries.
How finished-dose responsibility usually maps to supplier reality
- FDA label holder: the company on the approved labeling.
- Manufacturing sites: often include a drug substance site and a sterile drug product site; these can be different entities.
- CMO/sterile fill-finish: may not be identifiable without site-level inspection records, regulatory filings, or distributor documentation.
What is the Orange Book status for palonosetron hydrochloride injection and who is listed?
Answer: The Orange Book lists approved versions by NDA and active ingredient strength, including patent and exclusivity codes when applicable. It does not directly provide a definitive “supplier list,” but it identifies the approved drug product holders that control supply.
A complete, accurate supplier mapping requires the NDA/ANDA product holders and their manufacturing site records linked to each application.
Which manufacturers supply palonosetron hydrochloride generics and how do ANDA holders affect sourcing?
Answer: ANDA applicants and their licensed manufacturers determine sourcing. Once FDA approves an ANDA, the listed manufacturer of record for each NDA section and manufacturing site becomes the controlling “supplier” for regulatory compliance, even if API comes from a third-party DMF holder.
Generic entry mechanics that drive supplier selection
- ANDA approval requires bioequivalence and chemistry/manufacturing controls for the sterile product.
- Sterile manufacturing capacity is a gating item. Many ANDA products rely on a limited number of aseptic fill-finish facilities qualified for oncology supportive care injectables.
- API procurement is governed by DMF cross-references; many finished-dose manufacturers buy from multiple API sources to manage continuity of supply.
What contract manufacturing and sterile fill-finish constraints apply to palonosetron injection?
Answer: Palonosetron hydrochloride injection is sterile and requires validated aseptic processing and container-closure integrity. Supplier competition is therefore more concentrated at the sterile fill-finish level than at the chemical synthesis level.
Key manufacturing/IP and QA factors shaping supplier availability
- Aseptic processing validation and sterility assurance.
- Extractables/leachables control tied to the container-closure system.
- Stability and compatibility testing across specific vial/label configurations.
- Batch release testing including appearance, pH, particulate matter, sterility, and assay specifications.
What suppliers are used for the drug substance (palonosetron hydrochloride) versus the sterile drug product?
Answer: The supply chain typically splits:
- Drug substance suppliers: chemical synthesis and purification providers for palonosetron hydrochloride.
- Drug product suppliers: sterile injectable manufacturers performing aseptic filling and packaging.
Why the split matters for procurement
- API supply disruptions do not always translate to immediate drug product shortages if sterile partners have inventory.
- Conversely, a stable API market can still lead to shortages if aseptic capacity or QA release capacity is constrained.
Which distributors and sourcing channels commonly carry palonosetron hydrochloride injection?
Answer: Distribution is largely handled by national and regional wholesalers and specialty distribution networks. Public distributor lists are not a reliable proxy for manufacturing “suppliers,” but they shape commercial availability.
Commercial sourcing patterns
- Contract purchasing by group purchasing organizations (GPOs).
- Direct distribution by NDA/ANDA holders in some channels.
- Specialty procurement for oncology supportive care products.
How does palonosetron hydrochloride compare to other 5-HT3 antagonists in supplier concentration?
Answer: Palonosetron injection shares sterile manufacturing constraints with other 5-HT3 antagonists, but supplier concentration varies by:
- Number of approved ANDAs per strength and presentation.
- Availability of validated sterile fill-finish capacity for the specific vial format.
- Time since last approval and subsequent facility qualification updates.
What are the main generic entry risks for palonosetron injection based on supplier barriers?
Answer: Supplier barriers for palonosetron injection generally involve sterile fill-finish readiness and consistent API-to-drug-product comparability controls.
Risk drivers
- Limited aseptic capacity for small-volume oncology supportive injectables.
- Tight control of formulation and container-closure compatibility.
- Validation and scale-up timelines that delay commercial launch.
Key Takeaways
- Palonosetron hydrochloride supply splits between API (DMF-supported chemical manufacturers) and finished-dose sterile injection manufacturers.
- “Suppliers” in practice are best defined by (1) the FDA drug product holder (NDA/ANDA) and (2) the manufacturing sites performing sterile fill-finish and release.
- Generic and originator supply can share API sources while using different sterile manufacturers; procurement risk is often located at the sterile fill-finish layer.
- A definitive, complete supplier list requires an Orange Book and site-level manufacturing mapping tied to each approved NDA/ANDA for palonosetron hydrochloride injection.
FAQs
- Is palonosetron hydrochloride injection available as an ANDA in the US, and which companies hold the approvals?
- What is the usual strength and presentation of palonosetron hydrochloride injection supplied for oncology supportive care?
- How do DMF-referenced API manufacturers influence the choice of sterile drug product suppliers?
- What sterile manufacturing requirements limit supplier availability for 5-HT3 antagonist injections like palonosetron?
- Do wholesalers control availability more than manufacturers for palonosetron injection during supply interruptions?
References
- FDA Orange Book. Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. Drug Master Files (DMF) information and guidance. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-master-files-dmfs
